Press release
Spinal Cord Injury Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Spinal Cord Injury Pipeline
In the Spinal Cord Injury Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Spinal Cord Injury NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Spinal Cord Injury Pipeline treatment landscape of the report, click here @ Spinal Cord Injury Pipeline Outlook- https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal Cord Injury Pipeline Report
DelveInsight's Spinal Cord Injury Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline treatment therapies.
The leading companies working in the Spinal Cord Injury Market include Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
Promising Spinal Cord Injury Pipeline Therapies in the various stages of development include KAI-1678, Tadalafil, FAB117-HC, NVG-291, MT-3921, ALMB-0166, NeuroAiD, KP-100IT, Elezanumab, and others.
March 2024:- NervGen Pharma- A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects. To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures.
March 2024:- Sint Maartenskliniek- The Effect of Vibrotactile Feedback on Exoskeleton Use in People With Motor Complete Spinal Cord Injury. This study aims to investigate the impact of providing discrete vibrotactile feedback related to weight shift and step initiation on exoskeleton use in individuals with motor-complete SCI.
Spinal Cord Injury Overview
Spinal Cord Injury (SCI) is a condition in which damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina) occurs. Spinal Cord Injury can be traumatic or non-traumatic.
For further information, refer to the detailed Spinal Cord Injury Unmet Needs, click here for Spinal Cord Injury Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Spinal Cord Injury Emerging Drugs Profile
• ES 135: Eusol Biotech
• MT-3921: Mitsubishi Tanabe Pharma Corporation
Spinal Cord Injury Pipeline Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. Phase III include, Eusol Biotech.
Request a sample and discover the recent advances in Spinal Cord Injury Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Spinal Cord Injury Segmentation- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Spinal Cord Injury Drugs and Companies
• KAI-1678: KAI Pharmaceuticals
• Tadalafil: Eli Lilly and Company
• FAB117-HC: Ferrer International S.A.
• NVG-291: NervGen Pharma
Spinal Cord Injury Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Spinal Cord Injury Therapeutics Market include-
Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
Dive deep into rich insights for drugs for the Spinal Cord Injury Pipeline, Click here @ Spinal Cord Injury Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Spinal Cord Injury Pipeline Report
• Coverage- Global
• Companies- Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
• Therapies- KAI-1678, Tadalafil, FAB117-HC, NVG-291, MT-3921, ALMB-0166, NeuroAiD, KP-100IT, Elezanumab, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Spinal Cord Injury Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Spinal Cord Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinal Cord Injury - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ES 135: Eusol Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MT-3921: Mitsubishi Tanabe Pharma Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NVG 291: NervGen Pharma
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. KAND-567: Kancera
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Spinal Cord Injury Key Companies
21. Spinal Cord Injury Key Products
22. Spinal Cord Injury- Unmet Needs
23. Spinal Cord Injury- Market Drivers and Barriers
24. Spinal Cord Injury- Future Perspectives and Conclusion
25. Spinal Cord Injury Analyst Views
26. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spinal Cord Injury Pipeline Outlook, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) here
News-ID: 3489471 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Spinal
Evolving Market Trends In The Spinal Fusion Devices Industry: Advancements In Sp …
The Spinal Fusion Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_
_x000D_
What Is the Expected Spinal Fusion Devices Market Size During the Forecast Period?_x000D_
Over the past few years, there has been a significant growth in the spinal fusion devices market. The market is projected…
Key Influencer in the Spinal Fusion Devices Market 2025: Rising Spinal Disorder …
What Is the Forecasted Market Size and Growth Rate for the Spinal Fusion Devices Market?
The market for spinal fusion devices has experienced significant growth in the past couple of years. Expectations are that it will rise from estimates of $7.85 billion in 2024 to approximately $8.31 billion in 2025, giving us a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this notable expansion during the historical period can…
Disposable Spinal Instrument Market: Revolutionizing Spinal Surgery with Hygiene …
Introduction
The medical device market has witnessed a surge in demand for disposable instruments, especially in areas where hygiene, precision, and efficiency are paramount. One such sector experiencing rapid growth is the disposable spinal instrument market. Spinal surgeries, being intricate and requiring high precision, have traditionally relied on reusable instruments. However, growing concerns about hygiene, infection control, and surgical efficiency have accelerated the shift toward disposable spinal instruments. These devices not…
Endoscopic Spinal Surgery Market: Minimally Invasive Solutions for Spinal Disord …
Global Endoscopic Spinal Surgery Market size was valued at US$ 667 Mn. in 2022 and the total revenue is expected to grow at a CAGR of 7.9% through 2022 to 2029, reaching nearly US$ 1137 Mn.
Endoscopic Spinal Surgery Market Overview:
Maximize Market Research is a research firm that has published a detailed analysis of the "Endoscopic Spinal Surgery Market". MMR in-depth market assessments in research reports consider significant technological advancements in…
Spinal Resilience: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
Market Outlook:
Charting Progress: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
The Acute Spinal Cord Injury Drug Pipeline Landscape sets its sights on a decade of advancements poised to redefine the trajectory of spinal resilience. This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to revolutionize the landscape of acute spinal cord injury treatment.
Market Drivers:
Neuroregeneration on the Horizon: At the forefront of the Acute Spinal Cord Injury Drug…
Spinal Laminoplasty Market - Revolutionizing spinal care with minimally invasive …
Newark, New Castle, USA: The "Spinal Laminoplasty Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Spinal Laminoplasty Market: https://www.growthplusreports.com/report/spinal-laminoplasty-market/8601
This latest report researches the industry structure, sales, revenue,…
